本帖最后由 老马 于 2013-3-13 13:43 编辑 / L4 \9 D: s, d# |9 u
: F$ F `) e4 Y. W
健择(吉西他滨)+顺铂+阿瓦斯汀# T2 p, Y( u. n a8 t
Gemzar +Cisplatin + Avastin
6 s( h6 [2 D d. U% G" G- v# L( Dhttp://annonc.oxfordjournals.org/content/21/9/1804.full+ `) g$ h1 v$ [+ U8 m# Z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' h: U }+ T zPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& p* H) ?% v' j& |, R: h5 } sResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. % a3 T2 j, h9 l, I, Y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 874)
# y" n% V1 q5 ~) f6 d% q& D G, r
华为网盘附件:
! u [5 j& m Q8 q: _【华为网盘】ava.JPG' t' _5 J, ^. |; V: [1 W
|